Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

davutamig (REGN5093)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Regeneron

Drug class:

c-MET inhibitor

Related drugs:

‹

›

MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria REGN5093 Sensitive : C2	REGN5093 Sensitive: C2 – Inclusion Criteria REGN5093 Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria REGN5093 Sensitive : C2	REGN5093 Sensitive: C2 – Inclusion Criteria REGN5093 Sensitive : C2
MET amplification + MET overexpression	Non Small Cell Lung Cancer	MET amplification + MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials REGN5093 Sensitive : C3	REGN5093 Sensitive: C3 – Early Trials REGN5093 Sensitive : C3
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials REGN5093 Sensitive : C3	REGN5093 Sensitive: C3 – Early Trials REGN5093 Sensitive : C3